Can Adma Biologics Incorporated (NASDAQ:ADMA)’s Tomorrow be Different? The Stock Had Increase in Shorts

June 20, 2017 - By Clifton Ray

 Can Adma Biologics Incorporated (NASDAQ:ADMA)’s Tomorrow be Different? The Stock Had Increase in Shorts

Investors sentiment decreased to 0.57 in 2016 Q4. Its down 0.18, from 0.75 in 2016Q3. It dropped, as 0 investors sold ADMA Biologics Inc shares while 7 reduced holdings. 0 funds opened positions while 4 raised stakes. 7.94 million shares or 1.17% less from 8.03 million shares in 2016Q3 were reported.
Geode Mgmt Lc holds 23,282 shares. Consonance L P owns 1.27M shares or 0.72% of their US portfolio. Vanguard Group stated it has 0% of its portfolio in ADMA Biologics Inc (NASDAQ:ADMA). Spark Investment Limited Liability owns 13,380 shares. Franklin Inc reported 359,499 shares or 0% of all its holdings. Tower Rech Cap Ltd Liability Corporation (Trc) owns 785 shares or 0% of their US portfolio. Aisling Ltd Limited Liability Company invested in 3.61 million shares or 4.29% of the stock. State Bank Of America Corp De has 1 shares. Morgan Stanley holds 8,237 shares or 0% of its portfolio. Fmr Ltd Liability Co accumulated 0% or 423,100 shares. Perceptive Limited Liability invested 0.26% of its portfolio in ADMA Biologics Inc (NASDAQ:ADMA). 856 were reported by Blackrock Invest Ltd. Weiss Multi accumulated 100,000 shares. The New York-based Prelude Mgmt Limited Liability Co has invested 0.02% in ADMA Biologics Inc (NASDAQ:ADMA). Iguana Health Mngmt Ltd Liability has invested 0.31% of its portfolio in ADMA Biologics Inc (NASDAQ:ADMA).

The stock of Adma Biologics Incorporated (NASDAQ:ADMA) registered an increase of 10.75% in short interest. ADMA’s total short interest was 68,000 shares in June as published by FINRA. Its up 10.75% from 61,400 shares, reported previously. With 36,700 shares average volume, it will take short sellers 2 days to cover their ADMA’s short positions. The short interest to Adma Biologics Incorporated’s float is 2.08%.

About 77 shares traded. ADMA Biologics Inc (NASDAQ:ADMA) has declined 37.56% since June 20, 2016 and is downtrending. It has underperformed by 54.26% the S&P500.

ADMA Biologics, Inc. is a late-stage biopharmaceutical firm that develops, makes and intends to market specialty plasma biologics for the treatment and prevention of infectious diseases. The company has market cap of $40.32 million. The Firm is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. It currently has negative earnings. The Company’s divisions include Plasma Collection Centers, which includes its activities in Georgia; Research and Development, which includes its plasma development activities in New Jersey, and Corporate.

ADMA Biologics Inc (NASDAQ:ADMA) Ratings Coverage

Among 2 analysts covering ADMA Biologics (NASDAQ:ADMA), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. ADMA Biologics had 5 analyst reports since September 9, 2015 according to SRatingsIntel. The firm has “Market Perform” rating given on Monday, August 1 by Raymond James. Maxim Group upgraded the shares of ADMA in report on Monday, January 23 to “Buy” rating. Maxim Group maintained ADMA Biologics Inc (NASDAQ:ADMA) on Thursday, September 17 with “Buy” rating. The stock of ADMA Biologics Inc (NASDAQ:ADMA) has “Strong Buy” rating given on Wednesday, September 9 by Raymond James. The stock has “Hold” rating by Maxim Group on Monday, August 1.

More notable recent ADMA Biologics Inc (NASDAQ:ADMA) news were published by: which released: “SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation …” on August 01, 2016, also with their article: “Shareholder Alert: Monteverde & Associates PC Announces An Investigation Of …” published on March 27, 2017, published: “ADMA Biologics to Present at Jefferies 2017 Healthcare Conference” on May 25, 2017. More interesting news about ADMA Biologics Inc (NASDAQ:ADMA) were released by: and their article: “BRIEF-ADMA Biologics Inc files for resale of 6.04 million shares of co’s …” published on June 16, 2017 as well as‘s news article titled: “ADMA Biologics to acquire certain assets from Biotest Pharmaceuticals” with publication date: January 23, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.